Shares of Momenta Pharmaceuticals Inc. MNTA, +5.04% rocketed 69% into record territory in premarket trading Wednesday, after the biotechnology company announced an agreement to be acquired by Johnson & Johnson JNJ, +0.73% in a deal valued at $6.5 billion. Under terms of the deal, J&J will pay $52.50 for each Momenta share outstanding, representing a 70.4% premium to Tuesday's closing price of $30.81. J&J's stock gained 0.2% ahead of the open. The deal is expected to close in the second half of 2020. J&J said the acquisition provides its Janssen Pharmaceuticals business an opportunity to broaden its leadership in immune-mediated diseases and expand into the autoantibody-driven disease business. The deal includes full global rights to Momenta's nipocalimab, a clinically validated anti-FcRn antibody, which allows Janssen to reach more patients by pursuing indications across many autoimmune diseases. Momenta's stock has soared 56.2% year to date through Tuesday, while J&J shares have gained 2.9% and the S&P 500 SPX, +0.23% has advanced 4.9%.
Reprinted from marketwatch, the copyright all reserved by the original author.
면책 조항: 본 게시글에 표현된 견해는 전적으로 작성자의 견해이며 Followme의 공식 입장을 대변하지 않습니다. Followme는 제공된 정보의 정확성, 완전성 또는 신뢰성에 대해 책임을 지지 않으며, 서면으로 명시적으로 언급되지 않는 한 해당 내용을 기반으로 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다.
더 오래된 의견은 없습니다. 소파를 가장 먼저 잡으십시오.